NICE updates alteplase guidance

New guidance from NICE recommends alteplase (Actilyse) for the treatment of ischaemic stroke if administered within 4.5 hours of onset of symptoms and if intracranial haemorrhage has been ruled out.

Intracranial haemorrhage should be excluded before use of alteplase. | SCIENCE PHOTO LIBRARY
Intracranial haemorrhage should be excluded before use of alteplase. | SCIENCE PHOTO LIBRARY

The NICE recommendations are made on the proviso that the drug is used within the terms of its marketing authorisation. Treatment with alteplase should be initiated as early as possible after the onset of symptoms. Intracranial haemorrhage should be excluded using appropriate imaging techniques.

Licence extension

The update to the NICE guidance follows a revision to the licensed indications for alteplase which extends the time period within which the drug can be administered from three hours to 4.5 hours.

The appraisal committee concluded that alteplase administered between 0 and 4.5 hours after onset of stroke symptoms was an effective treatment for acute ischaemic stroke because it decreased the probability of death or dependence. It also considered the fact that extension of the treatment window may enable increased access to treatment with alteplase for patients in remote or rural locations.

Further details
NICE guidance on alteplase for stroke

Further information
View alteplase drug record

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases